Mediar Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-23.
Mediar Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 23, 2025. The filing reports $37.85M sold. Its industry group is Biotechnology. It names Rahul Ballal (Executive Officer, Director), Cassidy Blundell (Director), Marie-Claire Peakman (Director) (SEC Form D, December 23, 2025).
Sell to companies like Mediar Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Mediar Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Mediar Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in December 2025, largest first.
Get an email when Mediar Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Mediar Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Mediar Therapeutics, Inc. →Get the full cited report on Mediar Therapeutics, Inc.
What the filing shows about Mediar Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mediar Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Mediar Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $37.85M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Rahul Ballal is named as Executive Officer and Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Cassidy Blundell is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Marie-Claire Peakman is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Adam Cotton is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Maina Bhaman is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Andreas Jurgeit is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Bharat Srinivasa is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Simon Sturge is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
Allan Marchington is named as Director on the Form D that Mediar Therapeutics, Inc. filed with the SEC on 23 December 2025, one of 9 people that filing names.
9 people named on the filing — 1 holding an executive role and 8 as directors only.
Named as of the 2025-12-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Mediar Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mediar Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mediar Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Mediar Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Mediar Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Mediar Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
https://mentionfox.com/funding/mediar-therapeutics-inc-form-d-25000001